IL6, interleukin 6, 3569

N. diseases: 2367; N. variants: 22
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE At 2 months post-surgery, intra-articular evidence of CTXII, IL1β, IL6, TNFα, and IFNγ was evaluated using a multiplex magnetic capture technique, and histological evidence of OA was assessed via a quantitative histological scoring technique.<b>Results</b>: Elevated levels of CTXII and IL6 were found in MCLT+MMT knees relative to skin-incision and contralateral controls; however, animal age did not affect the severity of joint inflammation. 31438735 2020
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE IL-6: no change in healthy, metabolic disorders and arthritis, increased in cirrhosis and renal failure, decreased in PCOS + MS. IL-10: no change in healthy, IBD and metabolic disorders, increased in arthritis. 31060892 2020
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE Peptidyl arginine deiminase inhibition suppresses arthritis via decreased protein citrullination in joints and serum with the downregulation of interleukin-6. 30285515 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE The results showed that terpenes have promising biological effects in relation to the treatment of arthritis, with the 24 terpenes identified in our survey being effective in the modulation of inflammatory mediators important to the physiopathology of arthritis, such as IL-6, IL-17, TNF-α, NFκB, and COX-2, among others. 30668316 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 GeneticVariation disease BEFREE Using human OA knee chondrocytes in vitro, we asked, does chloramphenicol (1) activate autophagy in chondrocytes; (2) protect chondrocytes from IL-1β-induced apoptosis; and (3) reduce the expression of matrix metallopeptidase (MMP)-13 and IL-6 (markers associated with articular cartilage degradation and joint inflammation). 31764352 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE This study examined the effect of the mouse anti-IL-6 receptor antibody, MR16-1, for the treatment of arthritis and enthesitis in McH-lpr/lpr-RA1 mice. 31200688 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE These results suggest that TOV has significant anti-arthritic effects on collagen-induced arthritis in rats, which may be attributed to the inhibition of the levels of IL-1β, IL-6, IL-8, IL-17A, TNF-α, MMP-3 and MMP-9, and the increase of IL-10 in serum as well as down-regulation of the protein expression of COX-2 and iNOS in synovial tissues via suppressing the phosphorylation and degradation of IκB. 30831463 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Addition of IL-17A, IL-17F and TNFα to synovial fibroblasts from patients with inflammatory arthritis resulted in significant production of IL-6 and IL-8, which was reduced to a larger extent by combined blockade of IL-17A and IL-17F than blockade of IL-17A alone. 31850514 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE The results indicate that SHW could be used to improving arthritis by reducing inflammatory factors (IL-6 and TNF-alpha). 30606189 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Systematic supplement of exogenous IL-6 reversed h-L. reuteri-induced CIA suppression. 31644891 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. 31173610 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE The histopathological features, clinical score, paw swelling, as well as the production of pro-inflammatory cytokines including interleukin (IL)-1β, IL-6 and IL-17A were measured to determine the amelioration of butyrate on arthritis. 30660077 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE Rats treated with UP1306 showed statistically significant improvements in arthritis severity markers, including uCTX-II (91.4% vs. collagen-induced arthritis (CIA)), serum IL-1β, TNF-α, and IL-6 levels as well as synovial MMP-13. 30691120 2019
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE CDD-450 also accelerated TNF-α and IL-6 mRNA decay, inhibited inflammation in mice with cryopyrinopathy, and was as efficacious as global p38α inhibitors in attenuating arthritis in rats and cytokine expression by cells from patients with cryopyrinopathy and rheumatoid arthritis. 29549113 2018
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE The present study aims to clarify the influence of obesity on the action of IL-6 and to evaluate the efficacy of IL-6 signalling blockade in arthritis with obesity. 28421996 2018
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-6. 30336338 2018
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Concentrations of MMP-8 and of IL-6 in serum were elevated in patients with chronic RA reflecting joint inflammation and the burden of established RA. 29683364 2018
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE In addition, agmatine restored total protein and albumin and reduces TNF-α and IL-6 levels in arthritis rats. 28006753 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Finally, the role of IL-6 and TGF-β<sub>1</sub> changes from immunosuppressive in resolving arthritis to stimulatory very early in the development of RA. 28847766 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 AlteredExpression disease BEFREE Our results showed that FGF21 significantly alleviated the severity of arthritis by reducing cellular immune responses and exerted the similar anti-inflammatory effects with Adalimumab in decreasing the mRNA and protein expression levels of IL-2, IL-6 and IL-17. 28273637 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE These three cases suggest that anti-IL-6 receptor antibody may be an effective alternative to corticosteroids or TNFαi for the treatment of arthritis irAEs. 28830882 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Additionally, anti-IL-6/anti-IL-21 treatment of CIA mice during the arthritis induction phase reduced disease development more potent than IL-6 or IL-21 inhibition alone, as effective as anti-TNF treatment. 28158305 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE Treatment of CD11b<sup>-/-</sup> mice after establishment of the Treg/Th17 balance with an anti-IL-6 receptor mAb significantly suppressed the induction of Th17 cells and reduced arthritis severity. 28191643 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 Biomarker disease BEFREE We hypothesized that concomitantly administered anti-IL-6, anti-TNF-α and anti-IFN-γ antibodies would inhibit the development of arthritis in IL-17A-deficient mice. 28859307 2017
CUI: C0003864
Disease: Arthritis
Arthritis
0.100 GeneticVariation disease BEFREE These preclinical findings may provide insight into why patients with arthritis being treated with IL-6 inhibitors develop new onset psoriasis and why IL-6 blockade for the treatment of psoriasis has not been clinically effective. 27984037 2017